Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Class 2 Device Recall ZYM B Reagent (REF 70493)

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 


New Search Back to Search Results
  Class 2 Device Recall ZYM B Reagent (REF 70493) see related information
Date Initiated by Firm November 08, 2013
Date Posted January 27, 2014
Recall Status1 Terminated 3 on November 30, 2017
Recall Number Z-0841-2014
Recall Event ID 66931
Product ZYM B Reagent (REF 70493)

ZYM B reagent is an additional test used to reveal the results of some miniaturized biochemical test included in the API strips. The API product line is a standardized system combining several biochemical tests, which enables group or species identifications of microorganisms.
Code Information Lot numbers: 1002171010, 1002295110, 1002360360, 1002421440, 1002485410, 1001951820, 1002011320, and 1002071020.
Recalling Firm/
Manufacturer		 Biomerieux France Chemin De L'Or
Chemin De L'Orme
Marcy L'Etoile France
For Additional Information Contact Ryan LeMelle
314-731-8582
Manufacturer Reason
for Recall		 bioM¿rieux identified a visual defect and activity issue on the ZYM B reagent (REF 70493); leading to a false negative results of some API biochemical tests using the ZYM B reagent.
FDA Determined
Cause 2		 Under Investigation by firm
Action bioMerieux sent an Urgent Product Removal Notice letter dated November 15, 2013, to all affected customers. The letter identified the product, the problem, and the action to be taken by the customer. Customers were instructed to ensure the letter and guidance were distributed and received by all appropriate personnel in their organization, customers were instructed to discontinue use and destroy ZYM (B 70493), API NH (10400) API Listeria (10300) with ZYM B ampules having a visual defect. Customers still in possession of some kits of ZYM B (70493-Lots: 1) without visual defect that is used with API 20 Strep (20600), API Coryne (20900), API Staph (20500) and API ZYM (25200), have the option to: a) Use the kits of ZYM B (70493) still in your inventory with the following mandatory requirement for the API Strep and API Coryne: perform a daily quality control with the ATCC¿ strain described in the paragraph Reading and Interpretation of the package insert of each API strip prior to using the ZYM B ampules. b) Use the kits of ZYM B (70493) still in your inventory without any requirement with API Staph and API ZYM, or c) Discard all kits of ZYM B (70493) still in their inventory. If you are still in possession of some kits of API NH (10400-Lots: See Annex 1) without visual defect of ZYM B, you have the option to: a) Use the kits of API NH (10400) still in your inventory with the mandatory requirement: perform a daily quality control with the ATCC¿ strain 49917 Haemophilus paraphrophilus described in the paragraph Use of the reagents of the package insert of API NH prior to using the ZYM B ampules or, b) Discard all the kits of API NH (10400) still in your inventory. 5. If you are still in possession of some kits of API Listeria (10300-Lots: See Annex 1) without visual defect of ZYM B, we ask you to use the API Listeria (10300) still in your inventory with the mandatory requirement: perform a daily quality control with the ATCC¿ strain 33090 Listeria innocua as
Quantity in Commerce 39439 kits (includes ZYM B reagents, API Listeria * API NH kits)
Distribution Worldwide Distribution - USA (nationwide) and Internationally to U.S. Nationwide; Algerie, Argentina, Armenia, Australia, Austria, Azerbaidjian, Bahrain, Bangladesh, Belarus, Belgium, Benin, Bolivia, Brazil, Brunei, Bulgaria, Burkina Faso, Cambodia, Cameroon, Canada, Chad, Chile, China, Colombia, Democratic Republic of Congo, Costa Rica, Cote d'Ivorie, Germany, Czech Republic, Dominican Republic, Dutch Antilles, Dutch Antilles, Ecuador, Egypt, Republica De El Salvador, Estonia, Germany, Ethiopia, France, Gabon, Georgia, Germany, Greece, Guatemala, Guinea, Herzegovina, Honduras, Hungary, India, Germany, Indonesia, Iraq, Israel, Italy, Jamaica, Japan, Iraq, Kazakhstan, Kenya, Korea, Kosovo, Kuwait, Latvia, Lebanon, Libya, Lithuania, Macedonia, Malaysia, Malaysia, Malaysia, Mali, Malta, Mexico, Romania, Mongolia, Morocco, Mozambique, Singapore, Netherlands, Managua, Niamey Niger, Nigeria, Nigeria, Oman, Pakistan, Panama, Paraguay, Peru, Philippines, Philippines, Poland, Portugal, Puerto Rico, Qatar, Romania, Russia, Uganda, Kingdom of Saudi Arabia, Serbia, Singapore, Slovakia, South Africa, Spain, Sudan, Sweden, Switzerland, Syria, Tanzania, Italy, Thailand, Trinidad & Tobago, Tunisia, Turkey, Uganda, Ukraine, UAE, United Kingdom, Uruguay, Venezuela, Vietnam, Vietnam, Yemen and Zimbabwe
1 A record in this database is created when a firm initiates a correction or removal action. The record is updated if the FDA identifies a violation and classifies the action as a recall, and it is updated for a final time when the recall is terminated. Learn more about medical device recalls.
2 Per FDA policy, recall cause determinations are subject to modification up to the point of termination of the recall.
3 For details about termination of a recall see Code of Federal Regulations (CFR) Title 21 §7.55.
-
-